Korean J Med.
2009 Aug;77(2):152-156.
Current status of drug-resistant tuberculosis and its treatment
- Affiliations
-
- 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine, Seoul, Korea.
Abstract
- Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR)-TB and extensively drug resistant (XDR)-TB, poses a serious threat to global health because it requires treatment for a long duration and frequent hospitalization, and results in a considerable number of mortalities. In South Korea, MDR is observed in 2.7% of newly diagnosed TB cases and in 14% of re-treatment cases. In addition, 5~20% of MDR-TB could be categorized as XDR-TB. Treatment regimen for MDR or XDR-TB should include 4~5 drugs susceptible to isolated tuberculous bacilli and should be maintained at least 18 months after culture conversion. Pertinent combination of anti-TB drugs and solid compliance are the basis of successful treatment for MDR and XDR-TB patients.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Study on the Drug Susceptibility Test of Multi-Drug Resistant Tuberculosis Patients
- Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?
- Medical Management of Drug-Resistant Tuberculosis
- Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis
- Pediatric tuberculosis and drug resistance
